Department of Emergency, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China.
Clin Transl Oncol. 2012 Mar;14(3):214-20. doi: 10.1007/s12094-012-0786-2.
The ligand EphrinB2 and the corresponding receptor EphB4 are up-regulated and involved in tumour growth in various human cancers. However, little is known about how this receptor-ligand complex contributes to the progression of glioma. This prompted us to study the association between the expressions of EphrinB2 and EphB4, clinicopathological variables, and glioma patient outcome.
Immunohistochemical staining was performed to detect the expression patterns of EphrinB2 and EphB4 in the biopsies from 96 patients with primary gliomas. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients.
Immunohistochemical analysis revealed that the expression of EphrinB2 was significantly correlated with that of EphB4 (r=0.86, p=0.002). EphrinB2 and EphB4 were significantly associated with the Karnofsky performance scale (KPS) score and World Health Organization grades of patients with gliomas, respectively. Especially, the positive expression rates of EphrinB2 and EphB4 were significantly higher in patients with higher grade (both p=0.001) and lower KPS score (p=0.002 and 0.003, respectively). Multivariate Cox regression analysis revealed that EphrinB2 and EphB4 expressions were both independent prognostic factors for progress-free survival of glioblastoma patients (both p=0.02).
Our data indicated for the first time that EphrinB2 and EphB4 expressions increase according to the histopathological grade and KPS score of glioma, and their expression levels are related to the progression-free survival of glioblastoma patients.
配体 EphrinB2 和相应的受体 EphB4 在各种人类癌症中上调并参与肿瘤生长。然而，对于该受体-配体复合物如何促进神经胶质瘤的进展知之甚少。这促使我们研究 EphrinB2 和 EphB4 的表达与临床病理变量以及神经胶质瘤患者预后之间的关系。
对 96 例原发性神经胶质瘤患者的活检标本进行免疫组织化学染色，以检测 EphrinB2 和 EphB4 的表达模式。进行 Kaplan-Meier 生存分析和 Cox 回归分析以评估患者的预后。
免疫组织化学分析显示 EphrinB2 的表达与 EphB4 的表达呈显著正相关(r=0.86，p=0.002)。EphrinB2 和 EphB4 与神经胶质瘤患者的 Karnofsky 表现量表(KPS)评分和世界卫生组织分级显著相关。特别是 EphrinB2 和 EphB4 的阳性表达率在高级别患者中显著升高(均为 p=0.001)，在 KPS 评分较低的患者中也显著升高(p=0.002 和 0.003)。多变量 Cox 回归分析显示 EphrinB2 和 EphB4 的表达均是胶质母细胞瘤患者无进展生存期的独立预后因素(均为 p=0.02)。
我们的数据首次表明 EphrinB2 和 EphB4 的表达随着神经胶质瘤的组织病理学分级和 KPS 评分而增加，其表达水平与胶质母细胞瘤患者的无进展生存期相关。
